Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 20, 2025

Thrasos Therapeutics

RRID:SCR_004052

Type: Tool

Proper Citation

Thrasos Therapeutics (RRID:SCR_004052)

Resource Information

URL: https://www.cbinsights.com/company/thrasos-therapeutics

Proper Citation: Thrasos Therapeutics (RRID:SCR_004052)

Description: Private, clinical stage biotherapeutics company focused on delivering new solutions to individuals affected by kidney disease. They are committed to developing novel approaches to protect, treat and restore kidney function for this patient group. Company has designed specific class of peptide compounds that have shown excellent results in controlling experimental kidney diseases, notably, models of diabetic nephropathy (kidney damage associated with diabetes), and acute kidney injury. These proprietary peptides may therefore be able to prevent and treat acute kidney injury, as well as slow and possibly reverse the progression of diabetic nephropathy. They act to control apoptosis (programmed cell death), inflammation and fibrosis (formation of scar tissue).

Abbreviations: Thrasos

Synonyms: Thrasos Innovation Inc.

Resource Type: commercial organization

Keywords: Controlling experimental kidney diseases, biotherapeutics, clinical, peptide, treat acute kidney injury, reverse progression diabetic nephropathy

Related Condition: Kidney disease, Acute kidney injury, Diabetic nephropathy, Chronic kidney disease

Funding:

Resource Name: Thrasos Therapeutics

Resource ID: SCR_004052

Alternate IDs: nlx_158489

Old URLs: http://www.thrasos.com/

Record Creation Time: 20220129T080222+0000

Record Last Update: 20250519T203320+0000

Ratings and Alerts

No rating or validation information has been found for Thrasos Therapeutics.

No alerts have been found for Thrasos Therapeutics.

Data and Source Information

Source: SciCrunch Registry

Usage and Citation Metrics

We have not found any literature mentions for this resource.